Publications by authors named "Robert Burger"

Claim this Profile
V
Virtual elasto-plastic robot compliance to active environments.
Michael Panzirsch, Harsimran Singh, Xuwei Wu, Maged Iskandar, Anne Koepken, Robert Burger

Sci Robot· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
Charles N Landen, Ronald J Buckanovich, Michael W Sill, Robert S Mannel, Joan L Walker, Robert A Burger

J Clin Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Bhavana Pothuri, Sileny Han, Dana M Chase, Florian Heitz, Robert A Burger

Gynecol Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study.
Robert F Ozols, Brian N Bundy, Benjamin E Greer, Jeffrey M Fowler, Daniel Clarke-Pearson, Robert A Burger

J Clin Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study.
Larry J Copeland, Mark F Brady, Robert A Burger, William H Rodgers, Helen Q Huang

J Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
Benoit You, Christopher Purdy, Larry J Copeland, Elizabeth M Swisher, Michael A Bookman, Robert A Burger

J Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
Nefertiti C duPont, Danielle Enserro, Mark F Brady, Katherine Moxley, Joan L Walker, Robert A Burger

Gynecol Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of adjuvant treatment and survival outcomes in stage I uterine carcinosarcoma.
Lori Cory, Colleen Brensinger, Robert A Burger, Robert L Giuntoli, Mark A Morgan

Gynecol Oncol Rep· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Payal D Shah, Stephanie L Wethington, Cheyenne Pagan, Nawar Latif, Janos Tanyi, Robert A Burger

Gynecol Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.
Lari Wenzel, Kathryn Osann, Chelsea McKinney, David Cella, Giulia Fulci, Robert A Burger

J Natl Cancer Inst· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: A case series and systematic review of the literature.
Rachel Hilburg, Abdallah S Geara, Maylene Kefeng Qiu, Matthew B Palmer, Elaine Y Chiang, Robert A Burger

Clin Nephrol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Universal rules of life: metabolic rates, biological times and the equal fitness paradigm.
Joseph Robert Burger, Chen Hou, Charles A S Hall, James H Brown

Ecol Lett· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
Megan E Buechel, Danielle Enserro, Robert A Burger, Mark F Brady, Katrina Wade

Gynecol Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The "Far Left" of the Morphologic Spectrum of Ovarian High-grade Serous Carcinoma: Case Report of a Purely Noninvasive High-grade Serous Carcinoma Mimicking an Ovarian Serous Borderline Tumor.
Levon Katsakhyan, Ezra G Baraban, Kimberly L Dumoff, Robert A Burger, Rupal Parikh

Int J Gynecol Pathol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An increase in multi-site practices: The shifting paradigm for gynecologic cancer care delivery.
Katherine Hicks-Courant, Genevieve P Kanter, Robert L Giuntoli, Marilyn M Schapira, Justin E Bekelman, Robert Burger

Gynecol Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical and oncologic outcomes of minimally invasive surgery for stage I high-grade endometrial cancer.
Dimitrios Nasioudis, Quetrell D Heyward, Ashley F Haggerty, Robert L Giuntoli Ii, Robert A Burger

Surg Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target.
Stefano Pierini, Janos L Tanyi, Fiona Simpkins, Erin George, Mireia Uribe-Herranz, Robert Burger

JCI Insight· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
Dmitriy Zamarin, Robert A Burger, Michael W Sill, Daniel J Powell, Heather A Lankes

J Clin Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy.
Dimitrios Nasioudis, Emily M Ko, Ashley F Haggerty, Lori Cory, Robert L Giuntoli, Robert A Burger

Gynecol Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer.
Ying L Liu, Pier Selenica, Qin Zhou, Alexia Iasonos, Margaret Callahan, Robert A Burger

JCO Precis Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Robert L Coleman, Katelyn F Handley, Robert Burger, Graziela Zibetti Dal Molin, Robert Stagg

Gynecol Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radical hysterectomy is not associated with a survival benefit for patients with stage II endometrial carcinoma.
Dimitrios Nasioudis, Sruthi Sakamuri, Emily M Ko, Ashley F Haggerty, Robert L Giuntoli, Robert A Burger

Gynecol Oncol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced stage primary mucinous ovarian carcinoma. Where do we stand ?
Dimitrios Nasioudis, Benjamin B Albright, Emily M Ko, Ashley F Haggerty, Robert L Giuntoli, Robert A Burger

Arch Gynecol Obstet· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B Sibley, Robert A Burger

Clin Cancer Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Farolfi et al and Haines et al.
Krishnansu S Tewari, Bradley J Monk, Robert A Burger

J Clin Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis